STTK Overview

Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Wall Street analysts forecast STTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STTK is8.33 USD with a low forecast of 4.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Shattuck Labs Inc revenue for the last quarter amounts to 0.00 USD, decreased

Shattuck Labs Inc. EPS for the last quarter amounts to -0.12 USD, decreased -67.57

Shattuck Labs Inc (STTK) has 40 emplpoyees as of March 11 2026.

Today STTK has the market capitalization of 426.52M USD.